Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443559 | 1.00 | NR3C1 (0.69) | NR3C1PGR | |
| SCHEMBL442260 | 1.00 | NR3C1 (0.69) | NR3C1PGR | |
| SCHEMBL443560 | 1.00 | NR3C1 (0.69) | NR3C1PGR | |
| SCHEMBL14207128 | 1.00 | NR3C1 (0.69) | NR3C1PGR | |
| SCHEMBL411302 | 1.00 | NR3C1 (0.69) | NR3C1PGR | |
| SCHEMBL835082 | 0.81 | NR3C1 (0.67) | NR3C1PGR | |
| SCHEMBL836164 | 0.81 | NR3C1 (0.67) | NR3C1PGR | |
| SCHEMBL835081 | 0.81 | NR3C1 (0.67) | NR3C1PGR | |
| SCHEMBL835431 | 0.81 | NR3C1 (0.67) | NR3C1PGR | |
| SCHEMBL835430 | 0.81 | NR3C1 (0.67) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097384-B1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| US-8030340-B2 | Moderators of glucocorticoids receptor; antiinflamamtory agents; chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 263/4885 |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.